In animal tumor models, both CD4+ and CD8+ Tscm are implicated in anti-tumor efficacy; in humans, administration of CAR-T cells with enhanced Tscm phenotype leads to improved persistence of the engineered cells, as well as improved clinical outcome; and in healthy individuals Tscm exhibit greater proliferation and cytotoxic polyfunctionality with a higher frequency of the triple positive effector phenotype—elevation of IFNγ, IL-2, and tumor necrosis factor (TNF)α secretion—upon secondary antigen response, than do other Tmem-subsets [13–15,30,58–60]. This evidence concerns the gene CD4 and neoplasm.